Core Insights - 2025 is a significant year for China's innovative drug industry, marked by multiple major BD transactions that have sparked a new bull market for innovative drugs [1] - The number of new drugs under research in China has risen to the second highest globally, indicating a shift from being a follower to a leader in the innovative drug sector [1] Industry Developments - The recent surge in BD transactions is expected to drive growth and opportunities within the innovative drug market in China [1] - The transition of China’s innovative drug industry towards a leadership position reflects its increasing capabilities and competitiveness on a global scale [1] Future Directions - Insights from industry leaders, such as Chris Shim from Veeva, will help explore the development opportunities and future directions for China's innovative drug sector [1]
对话Veeva研发与质量业务亚太总经理Chris Shim：中国创新药企的全球化路径
Jing Ji Guan Cha Bao·2025-10-09 11:19